Huaju Yang
Rendong Huang2†
Zheran Liu
Xingchen Peng- 1Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- 2Hangzhou Linan Guorui Health Industry Investment Co., Ltd, Hangzhou, Zhejiang, China
- 3Department of Oncology, Chengdu Integrated TCM & Western Medicine Hospital, Chengdu First People’s Hospital, Chengdu, Sichuan, China
- 4Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- 5Department of Medical Education, Kweichow Moutai Hospital, Zunyi, Guizhou, China
By Yang H, Huang R, Zhang P, Liu Y, Liu Z, He J and Peng X (2024)Front. Immunol. 15:1439231. doi: 10.3389/fimmu.2024.1439231
The funder “1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University (ZYYC23006)” to “Xingchen Peng” was erroneously omitted.
The corrected Funding statement should read as follows:
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The work was supported by A single center, open, randomized controlled clinical trial of Moutai Liquor regulating oral microorganisms to alleviate radiation-induced oral mucosa damage in head and neck squamous cell carcinoma (MTyk-2022-03), the National Key Research and Development Program of China (2021YFE0206600), National Natural Science Foundation of China (82172842 and 81672386), Sichuan Science and Technology Program (2022YFSY0012, 2021ZYCD011, 2021YFSY0008, 2021CDDZ-25, 2021CDZG-24), Chengdu International Science and Technology Cooperation Program (2022-GH03-00004-HZ), West China Nursing Discipline Development Special Fund Project (HXHL21008), The Post-Doctor Research Project, West China Hospital, Sichuan University (2020HXBH119), Translational Medicine Fund of West China Hospital (CGZH19002), The China Medical Board (Grant 22-482), the Clinical Research Incubation Project of West China Hospital (20HXFH037), and the 1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University (ZYYC23006)”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: immune checkpoint inhibitors (ICIs), statins, immune-related adverse events(irAEs), cancer, food and drug administration adverse event reporting system database (FAERS)
Citation: Yang H, Huang R, Zhang P, Liu Y, Liu Z, He J and Peng X (2026) Correction: Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database. Front. Immunol. 16:1768895. doi: 10.3389/fimmu.2025.1768895
Received: 16 December 2025; Accepted: 17 December 2025;
Published: 08 January 2026.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2026 Yang, Huang, Zhang, Liu, Liu, He and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jiagang He, NTA1MTgxMDc4QHFxLmNvbQ==; Xingchen Peng, cHh4MjAxNEAxNjMuY29t
†These authors have contributed equally to this work and share first authorship